TrialClinical pharmacology in drug development2021

A Randomized, Double-Blind, Parallel-Group, Phase 1 Clinical Trial Comparing the Pharmacokinetic, Safety, and Immunogenicity of the Biosimilar HS016 and the Originator Adalimumab in Chinese Healthy Male Subjects.

Guoying Cao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.